| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The primary targets of Sennidin A include HCV NS3 helicase, a key enzyme in hepatitis C virus replication. The compound also targets the PI3K/Akt signaling pathway, inducing phosphorylation of Akt and GLUT4 translocation. This leads to increased glucose incorporation in adipocytes in an insulin-independent manner.
|
|---|---|
| ln Vitro |
In vitro, Sennidin A inhibits HCV NS3 helicase with an IC₅₀ of 0.8 μM. It induces the phosphorylation of Akt and GLUT4 translocation, stimulating glucose incorporation. In rat adipocytes, Sennidin A stimulates glucose incorporation in a PI3K- and Akt-dependent but IR/IRS1-independent manner. The compound also shows necrosis-avid imaging properties.
|
| ln Vivo |
In vivo studies on Sennidin A are limited. Based on its mechanism of action, the compound may have potential in the treatment of HCV infection and metabolic disorders. Its glucose transport-stimulating activity suggests potential in diabetes research. Further in vivo studies are needed to fully characterize its pharmacological effects and therapeutic potential.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, Sennidin A is tested against HCV NS3 helicase. The helicase enzyme is incubated with varying concentrations of the compound and a DNA/RNA substrate in the presence of ATP. Helicase activity is measured by monitoring the unwinding of the substrate using fluorescence polarization or gel-based assays. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, Sennidin A is typically tested on adipocytes or HCV-infected cell lines. Adipocytes are treated with the compound at various concentrations (typically 1-100 μM) and glucose uptake is measured using 2-deoxyglucose uptake assays. Phosphorylation of Akt and GLUT4 translocation are assessed by Western blotting. HCV replication inhibition can be evaluated in HCV replicon cell lines.
|
| Animal Protocol |
In vivo animal experiments for Sennidin A have not been extensively reported. Based on its mechanism as an HCV NS3 helicase inhibitor, potential experimental models include HCV-infected mouse models. The compound could be administered orally or intraperitoneally, with viral load and liver function parameters assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Sennidin A are limited. As a dimeric anthraquinone with a molecular weight of 538.46 g/mol and formula C₃₀H₁₈O₁₀, it is expected to have moderate oral bioavailability. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Sennidin A are limited. As a natural anthraquinone, it may have cytotoxic effects at high concentrations. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Reports indicate that senna (Senna alexandrina) contains sennoside A, and relevant data is available for reference.
Sennidin A is a research-use only compound and has not been approved for clinical applications. It is also known as番泻苷元A in Chinese. The compound is isolated from Cassia angustifolia (senna) leaves. Its molecular weight is 538.46 and formula is C₃₀H₁₈O₁₀. It is available from various research chemical suppliers. |
| Molecular Formula |
C30H18O10
|
|---|---|
| Exact Mass |
538.09
|
| CAS # |
641-12-3
|
| Related CAS # |
Sennidin B;517-44-2
|
| PubChem CID |
92826
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
801.8±65.0 °C at 760 mmHg
|
| Flash Point |
452.6±30.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.806
|
| LogP |
8.24
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
40
|
| Complexity |
977
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C1C2C(=C([H])C([H])=C([H])C=2C([H])(C2C([H])=C(C(=O)O[H])C([H])=C(C=21)O[H])C1([H])C2C([H])=C([H])C([H])=C(C=2C(C2C(=C([H])C(C(=O)O[H])=C([H])C1=2)O[H])=O)O[H])O[H]
|
| InChi Key |
JPMRHWLJLNKRTJ-FGZHOGPDSA-N
|
| InChi Code |
InChI=1S/C30H18O10/c31-17-5-1-3-13-21(15-7-11(29(37)38)9-19(33)25(15)27(35)23(13)17)22-14-4-2-6-18(32)24(14)28(36)26-16(22)8-12(30(39)40)10-20(26)34/h1-10,21-22,31-34H,(H,37,38)(H,39,40)/t21-,22-/m1/s1
|
| Chemical Name |
(9R)-9-[(9R)-2-carboxy-4,5-dihydroxy-10-oxo-9H-anthracen-9-yl]-4,5-dihydroxy-10-oxo-9H-anthracene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
